<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01983748</url>
  </required_header>
  <id_info>
    <org_study_id>DERMA-ER-DC 08</org_study_id>
    <nct_id>NCT01983748</nct_id>
  </id_info>
  <brief_title>Dendritic Cells Plus Autologous Tumor RNA in Uveal Melanoma</brief_title>
  <official_title>A NON-COMMERCIAL, MULTICENTER, RANDOMIZED, TWO-ARMED, OPEN-LABEL PHASE III STUDY TO EVALUATE THE ADJUVANT VACCINATION WITH TUMOR RNA-LOADED AUTOLOGOUS DENDRITIC CELLS VERSUS OBSERVATION OF PATIENTS WITH RESECTED MONOSOMY 3 UVEAL MELANOMA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Erlangen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital Lübeck</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital Munich</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universitätsklinikum Hamburg-Eppendorf</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital Homburg/Saar</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universitätsklinikum Köln</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital Tuebingen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Essen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wuerzburg University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Erlangen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients suffering from uveal melanoma (typed positive for monosomy 3 and without evidence
      for metastases) will be vaccinated over a period of 2 years with Dendritic Cell loaded with
      autologous Tumor RNA.

      200 patients will be included. The Trial is an open multicenter Phase III Trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Trial arm A (DCaT-RNA) = Experimental intervention: Patients in arm A receive 8 vaccinations
      over a period of 2 years consisting of autologous, mature, monocyte-derived Dendritic Cells
      loaded with autologous tumor RNA (20 mio DC per vaccination); cells are given via intravenous
      infusions; vaccinations are followed by a 1 year observation (staging every 3 months)

      Trial arm B (Observation) = Control: Patients in arm B receive standard care (observation
      only with staging every 3 months)
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prolongation of disease free survival</measure>
    <time_frame>Clinical staging every 3 months from date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 36 months.</time_frame>
    <description>Skin, lymph node and ophtalmological inspection , medical history, laboratory, and abdominal sonography will be performed every 3 months, chest x ray will be performed every 6 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prolongation of Overall survival</measure>
    <time_frame>Assessment every 3 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Assessment for induction of immune responses</measure>
    <time_frame>The induction of immune responses will be researched in selected patients (in a minimum of 15 survivors per trial arm) 2 years after randomization.</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Uveal Melanoma</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Biological/Vaccine; Autologous Dendritic Cells loaded with autologous Tumor RNA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Control, Standard of care, which is clinical control every 3 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Autologous Dendritic Cells loaded with autologous Tumor RNA</intervention_name>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must suffer from melanoma of the uvea (stage T2, T3 and T4 [AJCC TNM grading
             2009]).

          -  Uveal melanoma must be resected and display a monosomy for chromosome 3 (will be
             determined by a validated qualitative analysis of loss of heterozygosity). Tumor
             material has to be stored appropriately in RNAlater solution for RNA preparation.

          -  The patient has to be free of detectable tumor at the time point of study enrollment
             (adjuvant setting), as assessed by clinical inspection, abdominal sonography, chest
             X-ray and evaluation of the tumor-marker S-100..

          -  Patients must have a WHO performance status of 0, 1 or 2 and must be in stable medical
             condition.

          -  Patients must be between 18 and 75 years old and must be able and willing to give
             informed consent.

          -  Women of child-bearing age must have a negative pregnancy test, and must oblige to use
             effective contraception until at least 4 weeks after the last vaccination.

          -  Patients must be willing to get hospitalized for at least 4 hours following
             vaccination(s), and to cooperate for the whole period of the trial.

          -  Patients must have fully recovered from surgery.

          -  Signed informed consent

        Exclusion Criteria:

          -  Any other major serious illness [e.g. active systemic infections, immunodeficiency
             disease, clinically significant heart disease, respiratory disease, bleeding
             disorders, cancer etc.] or a contraindication to leukapheresis.

          -  Evidence for HIV-1, HIV -2, HTLV-1, HBV, or HCV infection.

          -  Active autoimmune disease (such as but not limited to Lupus erythematosus, autoimmune
             thyroiditis or uveitis, multiple sclerosis, inflammatory bowel disease). Vitiligo and
             pathological laboratory results (autoantibodies) without clinical symptoms are,
             however, not an exclusion criterion.

          -  Previous splenectomy or radiation therapy to the spleen.

          -  Patients with organ allografts.

          -  Concomitant treatment with chemotherapy, immunotherapy, any investigational drug and
             paramedical substances. Patients may receive concomitant medications to control
             symptoms such as analgetics, antihypertensive medication, etc.

          -  History of other active malignant neoplasm within the preceding 5 years (excluding
             non-melanoma skin cancer or carcinoma in situ of the cervix).

          -  Organic brain syndrome or significant psychiatric abnormality which would impede
             informed consent and / or AND preclude participation in the full protocol and follow
             up.

          -  Positive pregnancy test / Pregnancy or lactation. If pregnancy occurs during the
             course of the trial to female patients in arm A or B, the patient has to be excluded.

          -  Detection of metastases. If uveal melanoma metastases appear during the course of the
             trial, the patient has to be excluded.

          -  Lack of compliance of the patient.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gerold Schuler, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Erlangen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Schuler-Thurner Beatrice, MD</last_name>
    <phone>0049 9131 85</phone>
    <phone_ext>45833</phone_ext>
    <email>beatrice.schuler-thurner@uk-erlangen.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Schuler Gerold, Prof.</last_name>
    <phone>0049 9131 85</phone>
    <phone_ext>33661</phone_ext>
    <email>gerold.schuler@uk-erlangen.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Dept. of Dermatology, University Hospital</name>
      <address>
        <city>Erlangen</city>
        <state>Bayern</state>
        <zip>90154</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Department of Ophtalmology</name>
      <address>
        <city>Erlangen</city>
        <state>Bayern</state>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Harald Knorr, Prof.</last_name>
      <phone>0039 9131 85</phone>
      <phone_ext>44728</phone_ext>
      <email>harald.knorr@uk-erlangen.de</email>
    </contact>
    <contact_backup>
      <last_name>Stoll Barbara, Study nurse</last_name>
      <email>barbara.stoll@uk-erlangen.de</email>
    </contact_backup>
    <investigator>
      <last_name>Friedrich Kruse, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Harald Knorr, Prof.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ralph Meiller, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Department of Ophtalmology</name>
      <address>
        <city>Würzburg</city>
        <state>Bayern</state>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thomas Ach, MD</last_name>
      <phone>0049 931 201</phone>
      <phone_ext>206 28</phone_ext>
      <email>ach_t@ukw.de</email>
    </contact>
    <investigator>
      <last_name>Thomas Ach, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Felix Guggenmoos-Schreyer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Städtisches Klinikum</name>
      <address>
        <city>Dessau</city>
        <zip>06847</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christiane Kneifel, MD</last_name>
      <phone>0049-340 - 501 4560</phone>
      <email>christiane.kneifel@klinikum-dessau.de</email>
    </contact>
    <investigator>
      <last_name>Lothar Krause, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Department of Ophtalmology</name>
      <address>
        <city>Essen</city>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefan Kreis, MD</last_name>
      <phone>0049 201 7238</phone>
      <phone_ext>3471</phone_ext>
      <email>stefan.kreis@uk-essen.de</email>
    </contact>
    <contact_backup>
      <last_name>Sandra Schindler-Drongowski</last_name>
      <phone>0049 201 - 723</phone>
      <phone_ext>2930</phone_ext>
      <email>Sandra.Schindler-Drongowski@uk-essen.de</email>
    </contact_backup>
    <investigator>
      <last_name>Norbert Bornfeld, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Claudia Metz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Department of Ophtalmology</name>
      <address>
        <city>Homburg/Saar</city>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Metzinger, Study nurse</last_name>
      <phone>0049 6841 16</phone>
      <phone_ext>22387</phone_ext>
      <email>Augenklinik.studienarzt@uks.eu</email>
    </contact>
    <investigator>
      <last_name>Berthold Seitz, Prof.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Arne Viestenz, PD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Department of Ophtalmology</name>
      <address>
        <city>Lübeck</city>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Friederike vom Ende, MD</last_name>
      <phone>0049 451 500 22</phone>
      <phone_ext>11</phone_ext>
      <email>friederike.vomEmde@uk-sh.de</email>
    </contact>
    <investigator>
      <last_name>Salvatore Grisanti, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Friederike vom Ende, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Department of Ophtalmology</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ulrike Hagemann, Study nurse</last_name>
      <phone>0049 7071 29837</phone>
      <phone_ext>30</phone_ext>
      <email>ulrike.hagemann@med.uni-tuebingen.de</email>
    </contact>
    <contact_backup>
      <last_name>Daniela Suesskind, MD</last_name>
      <phone>0049 7071 29837</phone>
      <phone_ext>30</phone_ext>
      <email>daniela.suesskind@med.uni-tuebingen.de</email>
    </contact_backup>
    <investigator>
      <last_name>Ulrich Bartz-Schmidt, Prof.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>PD Daniela Süsskind, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Schuler-Thurner B, Bartz-Schmidt KU, Bornfeld N, Cursiefen C, Fuisting B, Grisanti S, Heindl LM, Holbach L, Keserü M, Knorr H, Koch K, Kruse F, Meiller R, Metz C, Meyer-ter-Vehn T, Much M, Reinsberg M, Schliep S, Seitz B, Schuler G, Süsskind D, Viestenz A, Wagenfeld L, Zeschnigk M. [Immunotherapy of uveal melanoma: vaccination against cancer. Multicenter adjuvant phase 3 vaccination study using dendritic cells laden with tumor RNA for large newly diagnosed uveal melanoma]. Ophthalmologe. 2015 Dec;112(12):1017-21. doi: 10.1007/s00347-015-0162-z. German.</citation>
    <PMID>26602097</PMID>
  </reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 17, 2013</study_first_submitted>
  <study_first_submitted_qc>November 7, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 14, 2013</study_first_posted>
  <last_update_submitted>May 4, 2017</last_update_submitted>
  <last_update_submitted_qc>May 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Erlangen</investigator_affiliation>
    <investigator_full_name>PD Dr. med. univ. Beatrice Schuler-Thurner</investigator_full_name>
    <investigator_title>Coordinating Investigator</investigator_title>
  </responsible_party>
  <keyword>Uveal Melanoma, Monosomy 3</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Uveal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

